Physician profile
Junsoo Lee
NPI 1427283563
$2,675.25
in general payments reported to CMS, 2019-2025
25 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $169 · 2021: $327 · 2022: $300 · 2023: $529 · 2024: $411 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $464.15 | 2019 | |
| Cardiovascular Systems INC. | $344.39 | 2019-2022 | |
| Boston Scientific Corporation | $337.09 | 2019-2024 | Comet, Rotapro, Opticross |
| Novartis Pharmaceuticals Corporation | $286.19 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $216.30 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $167.21 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $137.95 | 2025 | Aurora Ev-Icd Mri Surescan |
| Janssen Pharmaceuticals, INC | $86.95 | 2020-2024 | Xarelto |
| Amarin Pharma, INC. | $84.54 | 2019 | |
| Amgen INC. | $83.66 | 2022-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $76.97 | 2022-2025 | Camzyos, Eliquis |
| Medicomp INC | $58.03 | 2023 | Telepatch Cardiac Monitor |
| Esperion Therapeutics, INC. | $49.41 | 2021-2022 | |
| Novo Nordisk INC | $44.79 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Celonova Biosciences, INC. | $42.48 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.50 | 2024 | Jardiance |
| Bridgebio Pharma, INC. | $25.64 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $20.71 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $19.32 | 2019 | |
| Ge Healthcare | $18.53 | 2019 | |
| Scpharmaceuticals INC. | $18.38 | 2023 | |
| Terumo Medical Corporation | $18.16 | 2021 | |
| Pfizer INC. | $17.42 | 2019 | |
| Medtronic Vascular, INC. | $14.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junsoo Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.